Elizabeth I. Buchbinder

机构：Massachusetts General Hospital, Dana-Farber Cancer Institute, Global Cancer Institute · ORCID：0000-0002-7979-8953

发表论文 263 篇 · 总被引 14357 次 · h-index 40

代表论文

• A multi-adjuvant personal neoantigen vaccine generates potent immunity in melanoma (2025 · Cell · 被引 33)
• Urinary C-X-C-motif ligand 9 (CXCL9) in immune checkpoint inhibitor–associated acute interstitial nephritis (2025 · Kidney International · 被引 18)
• Randomized phase II study of neoadjuvant (neoadj) anti-PD-1 dostarlimab (D) vs. D + anti-TIM-3 cobolimab (C) in high-risk resectable melanoma (mel) (NEO-MEL-T): Primary analysis. (2025 · Journal of Clinical Oncology · 被引 9)
• A phase II study of the interleukin-6 (IL-6) receptor blocking antibody sarilumab (Sari) in combination with ipilimumab (Ipi), nivolumab (Nivo) and relatlimab (Rela) in patients with unresectable stage III or stage IV melanoma. (2025 · Journal of Clinical Oncology · 被引 8)
• 1601O 3-year survival with neoadjuvant-adjuvant pembrolizumab from SWOG S1801 (2025 · Annals of Oncology · 被引 5)
• Intratumoral vidutolimod as monotherapy or in combination with pembrolizumab in patients with programmed cell death 1 blockade–resistant melanoma: Final analysis from a phase 1b study (2025 · Cancer · 被引 4)